The Role of CtDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769431

Authors

Jacopo Costa

Alexandro Membrino

Carol Zanchetta

Simona Rizzato

Francesco Cortiula

Ciro Rossetto

Giacomo Pelizzari

Giuseppe Aprile

Marianna Macerelli

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS) enables comprehensive genetic profiling of tumours, including non-driver alterations that offer prognostic insights. LB can be applied in both early-stage disease settings, for the diagnosis and monitoring of minimal residual disease (MRD), and advanced disease settings, for monitoring treatment response and understanding the mechanisms behind disease progression and tumour heterogeneity. Currently, LB has limited use in clinical practice, primarily due to its significant costs, limited diagnostic yield, and uncertain prognostic role. The application of artificial intelligence (AI) in the medical field is a promising approach to processing extensive information and applying it to individual cases to enhance therapeutic decision-making and refine risk assessment.

References

Reck M, Hagiwara K, Han B, Tjulandin S, Grohe C, Yokoi T . ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. J Thorac Oncol. 2016; 11(10):1682-9. DOI: 10.1016/j.jtho.2016.05.036. View

Widman A, Shah M, Frydendahl A, Halmos D, Khamnei C, Ogaard N . Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024; 30(6):1655-1666. PMC: 7616143. DOI: 10.1038/s41591-024-03040-4. View

Li X, Li W, Lin J, Yan H, Tu H, Chen H . Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). Clin Lung Cancer. 2020; 22(2):100-109.e3. DOI: 10.1016/j.cllc.2020.11.001. View

Adams S, Stone E, Baldwin D, Vliegenthart R, Lee P, Fintelmann F . Lung cancer screening. Lancet. 2022; 401(10374):390-408. DOI: 10.1016/S0140-6736(22)01694-4. View

Chabon J, Hamilton E, Kurtz D, Esfahani M, Moding E, Stehr H . Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020; 580(7802):245-251. PMC: 8230734. DOI: 10.1038/s41586-020-2140-0. View

Razavi P, Li B, Brown D, Jung B, Hubbell E, Shen R . High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019; 25(12):1928-1937. PMC: 7061455. DOI: 10.1038/s41591-019-0652-7. View

Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G . Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9):1345-53. PMC: 4224589. DOI: 10.1097/JTO.0000000000000263. View

Uozu S, Imaizumi K, Yamaguchi T, Goto Y, Kawada K, Minezawa T . Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies. BMC Pulm Med. 2017; 17(1):175. PMC: 5719748. DOI: 10.1186/s12890-017-0514-3. View

Garcia-Pardo M, Makarem M, Li J, Kelly D, Leighl N . Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022; 127(4):592-602. PMC: 9381753. DOI: 10.1038/s41416-022-01776-9. View

10.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

11.

Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D . LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer. J Thorac Oncol. 2024; . DOI: 10.1016/j.jtho.2024.12.011. View

12.

Pellini B, Madison R, Childress M, Miller S, Gjoerup O, Cheng J . Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023; 29(22):4596-4605. PMC: 10643998. DOI: 10.1158/1078-0432.CCR-23-1578. View

13.

Franzi S, Seresini G, Borella P, Rafaniello Raviele P, Bonitta G, Croci G . Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives. Front Genet. 2023; 14:1254839. PMC: 10728669. DOI: 10.3389/fgene.2023.1254839. View

14.

Fernandes M, Cruz-Martins N, Machado J, Costa J, Hespanhol V . The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell Int. 2021; 21(1):675. PMC: 8680243. DOI: 10.1186/s12935-021-02382-0. View

15.

Papadimitrakopoulou V, Han J, Ahn M, Ramalingam S, Delmonte A, Hsia T . Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2019; 126(2):373-380. DOI: 10.1002/cncr.32503. View

16.

Assaf Z, Zou W, Fine A, Socinski M, Young A, Lipson D . A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023; 29(4):859-868. PMC: 10115641. DOI: 10.1038/s41591-023-02226-6. View

17.

Anagnostou V, Ho C, Nicholas G, Juergens R, Sacher A, Fung A . ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023; 29(10):2559-2569. PMC: 10579094. DOI: 10.1038/s41591-023-02598-9. View

18.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

19.

Page R, Drusbosky L, Dada H, Raymond V, Daniel D, Divers S . Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021; 23(1):72-81. DOI: 10.1016/j.cllc.2021.10.001. View

20.

Tang L, Li R, Wen H, Zhou Q, Xu C . Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer. Chin Med J Pulm Crit Care Med. 2024; 1(4):207-214. PMC: 11332816. DOI: 10.1016/j.pccm.2023.04.001. View